Last updated: October 18, 2026
Shire Pharmaceutical Development Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-02865, was an ANDA patent dispute in the U.S. District Court for the District of Delaware involving generic mesalamine delayed-release tablets, the generic equivalent of Shire’s Lialda product. Shire asserted patents covering Lialda’s multimatrix delivery system and controlled-release mesalamine formulation. The case was resolved without a reported merits judgment determining invalidity or noninfringement.
The commercial significance was tied to Lialda’s gastrointestinal delivery technology rather than to mesalamine’s active ingredient, which had long been known. Shire’s litigation strategy focused on formulation and release characteristics that delayed mesalamine release until the intestinal tract.
What drug and ANDA were involved in the Shire v. Amneal case?
The dispute concerned mesalamine 1.2-gram delayed-release tablets, the generic version of Lialda.
| Item |
Detail |
| Brand product |
Lialda |
| Active ingredient |
Mesalamine |
| Dosage form |
Delayed-release oral tablet |
| Strength |
1.2 grams |
| Reference sponsor |
Shire |
| Generic applicant |
Amneal Pharmaceuticals LLC |
| Regulatory pathway |
Abbreviated New Drug Application |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:15-cv-02865 |
| Filing period |
2015 |
| Litigation basis |
Hatch-Waxman Paragraph IV ANDA litigation |
Lialda uses a pH-dependent coating and a multimatrix core designed to release mesalamine throughout the colon. The formulation was intended to provide once-daily treatment for ulcerative colitis. The litigation therefore involved technical formulation limitations, not merely the identity of mesalamine.
What patents protected Lialda and were relevant to the dispute?
The Lialda patent estate included patents directed to controlled-release mesalamine formulations, tablet architecture, coatings and methods of treatment. The principal public Lialda patent family included the following patents:
| Patent |
General subject matter |
Nominal term profile |
| U.S. Patent No. 8,337,886 |
Mesalamine composition and controlled-release formulation |
Approximately 2028 |
| U.S. Patent No. 8,496,965 |
Mesalamine formulation and release characteristics |
Approximately 2028 |
| U.S. Patent No. 8,865,688 |
Mesalamine compositions and delivery systems |
Approximately 2028 |
| U.S. Patent No. 9,192,644 |
Continuation-family formulation claims |
Approximately 2028 |
| Related continuation patents |
Formulation and method-of-use claims |
Vary by patent and patent-term adjustment |
The asserted patent set must be distinguished from the broader Orange Book estate. Shire’s complaints in Lialda cases typically relied on claims directed to the multimatrix tablet, the enteric or pH-dependent coating, and the controlled release of mesalamine.
The active ingredient itself offered limited exclusionary value because mesalamine was an established compound. The commercial patent value rested on the formulation’s structure and release behavior.
How did the Hatch-Waxman process trigger the case?
Amneal’s ANDA filing included a Paragraph IV certification challenging one or more Lialda patents listed in the FDA’s Orange Book. A Paragraph IV certification states that the listed patent is invalid, unenforceable or would not be infringed by the proposed generic product.
Shire’s lawsuit followed within the statutory period. The filing triggered the Hatch-Waxman automatic stay, which generally prevents FDA approval of the ANDA for up to 30 months unless the court resolves the case earlier or the stay is otherwise altered. The litigation therefore created a regulatory barrier even before a final judgment on the patent claims.
The relevant legal issues would have included:
- Whether Amneal’s proposed mesalamine tablet fell within the asserted formulation claims.
- Whether the asserted claims were anticipated or obvious in view of prior mesalamine delivery systems.
- Whether the claims were adequately supported and enabled.
- Whether the formulation claims covered the product as described in Amneal’s ANDA.
- Whether any method-of-use claims applied to Amneal’s proposed labeling.
What was the litigation status and outcome?
The case did not produce a reported trial judgment resolving the asserted Lialda patents. The public litigation record reflects resolution through a stipulated or negotiated termination rather than a published decision holding the asserted claims invalid or not infringed.
That distinction matters. A dismissal or settlement does not establish that the patents were valid, enforceable or infringed. It also does not create a binding technical precedent for later Lialda ANDA cases.
The public docket does not provide a judicially determined generic launch date equivalent to a litigated judgment. Hatch-Waxman settlement terms are often confidential, and a docket termination alone does not establish the precise commercial terms agreed by the parties.
| Issue |
Public litigation implication |
| Invalidity |
No reported merits ruling invalidating the asserted patents |
| Noninfringement |
No reported merits ruling finding Amneal’s product noninfringing |
| Inequitable conduct |
No reported merits ruling |
| Settlement |
Case termination was not a merits adjudication |
| Generic launch date |
Not established by a reported trial judgment |
| Regulatory approval |
Separate from the litigation outcome and controlled by FDA review |
What was the Orange Book status of Lialda?
Lialda’s Orange Book protection was based primarily on formulation patents. FDA Orange Book listings are relevant because they identify patents that a generic applicant must address in its ANDA certification.
A listed patent can create a regulatory stay and litigation exposure, but Orange Book listing does not prove that the patent claims are valid or infringed. The distinction was central to the Lialda product line because the product’s principal protection came from formulation claims rather than a basic compound patent.
The FDA’s Orange Book records should be reviewed by product and patent number because listings can change over time through patent expiration, delisting, corrections or changes in product coverage. The relevant Lialda patents had expiration dates materially later than the older mesalamine compound and formulation patents, extending potential protection into the late 2020s.
How strong was Shire’s Lialda patent estate?
Shire’s estate was technically meaningful but narrower than a compound patent estate.
Strengths
The estate had several commercial advantages:
- It covered a differentiated oral delivery system rather than only the active ingredient.
- The claims were connected to product characteristics that could be evaluated through formulation testing.
- Multiple continuation patents created claim-set diversity.
- The patents extended beyond the earliest mesalamine patents.
- The claims could support Paragraph IV litigation against products using similar pH-dependent and multimatrix technology.
Weaknesses
The estate also had litigation vulnerabilities:
- Mesalamine delivery systems and enteric coatings were known before the asserted patents.
- Obviousness arguments could combine known mesalamine formulations with conventional delayed-release technologies.
- Narrow formulation claims can be avoided through changes to excipient composition, coating thickness, release profile or tablet architecture.
- Method-of-use claims may be limited by the generic product label and by the distinction between direct and induced infringement.
- The validity of later continuation claims depends on written-description support and the scope of the disclosed formulation technology.
The estate was stronger as a portfolio than as a single blocking patent. A generic applicant could face greater risk when multiple claims covered overlapping physical characteristics, but each patent still required separate analysis.
What formulation patents created generic entry risk?
The principal generic entry risk involved product-by-process and performance characteristics that could be tested against the ANDA product. Relevant claim categories included:
Multimatrix tablet claims
These claims generally focused on a tablet containing mesalamine distributed in a matrix with excipients controlling water penetration and drug release.
pH-dependent coating claims
The coating was designed to resist release in the stomach and upper gastrointestinal tract, with release beginning at a higher intestinal pH.
Controlled-release claims
These claims addressed the timing, location or rate of mesalamine release. Such claims could create infringement risk even where the generic product used different excipients if the claimed release profile was met.
Method-of-use claims
Lialda patents could also cover treatment of ulcerative colitis using specified dosing schedules or release characteristics. These claims presented a narrower risk profile because infringement depended in part on the proposed label and the generic manufacturer’s intended use.
Did the case involve biosimilar risk?
No. The case was not a biosimilar dispute.
Amneal’s product was a small-molecule generic subject to the Hatch-Waxman Act and an ANDA. Biosimilar litigation involves biological products, reference-product exclusivity, the Biologics Price Competition and Innovation Act, and FDA Purple Book listings. Lialda and mesalamine are not biologics, so biosimilar concepts do not apply to this case.
Which companies challenged Lialda patents?
Lialda faced a broader generic challenge from multiple ANDA applicants, including major generic manufacturers and specialty pharmaceutical companies. The relevant competitive group included companies such as Amneal, Teva, Mylan, Actavis and other applicants that pursued mesalamine delayed-release tablets.
Each case had to be analyzed separately because:
- ANDA formulations differed.
- The challenged patent sets were not identical.
- Litigation schedules varied.
- Settlement terms were frequently confidential.
- Generic launch dates could differ by applicant.
A settlement in one case did not necessarily eliminate litigation risk in another.
When did Lialda lose exclusivity?
Lialda’s commercial exclusivity did not end on a single date because several protections applied:
| Protection |
Effect |
| New-drug exclusivity |
Expired before the later formulation patent disputes |
| Early formulation patents |
Expired earlier than the later continuation patents |
| Orange Book patents |
Created separate approval and litigation barriers |
| Regulatory stay |
Could delay approval after a Paragraph IV filing |
| Later formulation patents |
Potentially extended patent protection into approximately 2028 |
| Settlement terms |
Could establish an earlier negotiated launch date |
The practical loss of exclusivity depended on FDA approval, patent expiration, Paragraph IV outcomes and private settlements. Patent expiry alone did not guarantee immediate generic market entry.
What revenue exposure did the litigation create?
Lialda was a material Shire gastrointestinal product, and generic entry threatened both price and volume.
The principal economic effects were:
- Price erosion after the first generic launch.
- Additional erosion as multiple manufacturers entered.
- Payer substitution toward lower-cost mesalamine products.
- Loss of market share to alternative mesalamine dosage forms.
- Pressure on Shire’s negotiating position with commercial insurers and pharmacy benefit managers.
- Declining value of later formulation patents once a noninfringing substitute became commercially viable.
The exposure depended on the timing of Amneal’s entry, the number of competing generic approvals and the availability of authorized or alternative generics. A settlement could preserve branded sales for a defined period while reducing litigation uncertainty.
How does the Shire v. Amneal estate compare with a compound patent?
A compound patent generally provides broader protection because it covers the active pharmaceutical ingredient across formulations and indications. Lialda’s estate was narrower but commercially relevant because it targeted the delivery system used by the branded product.
| Comparison |
Lialda formulation estate |
Compound patent estate |
| Scope |
Specific formulation or release characteristics |
Active ingredient across products |
| Design-around risk |
Relatively high |
Lower before expiration |
| Technical proof |
Formulation testing and claim construction |
Chemical identity |
| Generic vulnerability |
Higher if an alternative formulation works |
Lower |
| Portfolio value |
Depends on overlapping claims |
Often concentrated in one core patent |
| Post-expiration impact |
Can be bypassed by alternative delivery |
Usually broad generic access |
Key Takeaways
- Shire v. Amneal concerned generic mesalamine delayed-release tablets for Lialda.
- The case was a Hatch-Waxman Paragraph IV dispute in the District of Delaware.
- Shire’s protection focused on multimatrix, pH-dependent and controlled-release formulation technology.
- No reported merits decision invalidated the asserted patents or found Amneal’s product noninfringing.
- The case ended without a public judicial ruling establishing the precise commercial launch terms.
- The Lialda patent estate was narrower than a compound patent estate but could delay or complicate generic entry.
- The case involved a small-molecule generic, not a biosimilar.
- Lialda’s later formulation protection extended into approximately the late 2020s, subject to patent-specific term calculations and regulatory developments.
FAQs About Shire v. Amneal and Lialda
What was the case number for Shire v. Amneal?
The case number was 1:15-cv-02865 in the U.S. District Court for the District of Delaware.
Was Amneal accused of infringing a patent on mesalamine itself?
No. The commercial dispute centered on formulation and delivery technology for mesalamine delayed-release tablets, not a basic ownership right in mesalamine as an active ingredient.
Did Shire win a trial against Amneal?
No reported merits judgment established a Shire trial victory. The case terminated without a published decision resolving validity or infringement.
Could Amneal launch before all Lialda patents expired?
Potentially, but only through an earlier settlement launch date, a successful patent challenge, a noninfringing product design or another regulatory pathway that removed the applicable barrier.
Was the Lialda patent estate stronger than the Vyvanse patent estate?
The estates protected different technologies. Lialda relied primarily on formulation patents, while Vyvanse had protection centered on lisdexamfetamine and related uses. Relative strength depended on claim scope, prior art, ANDA design and remaining patent term.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
- U.S. Food and Drug Administration. (2024). Lialda prescribing information.
- U.S. District Court for the District of Delaware. (2015). Shire Pharmaceutical Development Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-02865.
- U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,337,886, 8,496,965, 8,865,688 and 9,192,644.
- Hatch-Waxman Amendments, Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
